14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 68 days ( -12.82 % )
Last Price $2.20 0 %
High/ Low $2.20 - $2.20 0%
Chg 7 Days N/A $2.20 $2.20
Chg 30 Days N/A $2.20 $2.20
Chg 12 mos -86.59 % $16.40 $2.20
Trend - 3 mos -1.22 % Width: 11.94 %
Trend - 12 mos -80.24 % Width: 167.54 %
Pred. range - 3 mos $2.08 - $2.32 -5.62 % - 5.64 %
Pred. range - 12 mos N/A - $0.597 -100.00 % - -72.85 %
Short MA avg 3 mos Sell Aug 15, 2022 - 59 days
Long MA avg 3 mos Sell Sep 21, 2022 - 33 days
Short/Long MA avg 3 mos Sell Sep 21, 2022 - 33 days
Short MA avg 12 mos Sell Aug 18, 2022 - 56 days
Long MA avg 12 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 12 mos Sell Nov 30, -1 - N/A days
Pivot Short Buy Aug 16, 2022 - 58 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Cortexyme Inc.

Cortexyme. Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis... CRTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT